Cefiderocol Treatment for Patients with Multidrug- and Carbapenem-Resistant Pseudomonas aeruginosa Infections in the Compassionate Use Program
Antimicrobial Agents and Chemotherapy · 18.07.2023 · 67 (7)
DOI: 10.1128/aac.00194-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 18.07.2023. Verfasst von Michael J Satlin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Transplant-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, New York,…. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Pseudomonas Infections. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cefiderocol is an option for infections caused by multidrug-resistant Pseudomonas aeruginosa , but its in vitro activity against these isolates and its clinical effectiveness for isolates with MICs of >1 μg/mL is unclear. We investigated the in vitro activity of cefiderocol against P. aeruginosa isolates collected from patients treated with cefiderocol through the compassionate use program and assessed physician-reported clinical response and 28-day all-cause mortality by cefiderocol MIC values. P. aeruginosa isolates underwent susceptibility testing to cefiderocol and comparator agents by using reference broth microdilution.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Transplant-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, New York, USA.
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Shionogi Inc., Florham Park, New Jersey, USA.
- Shionogi & Co., Ltd., Osaka, Japan.
ORCID-Profile: Michael J Satlin, Patricia J Simner, Simon Portsmouth
Zitieren
APA
Satlin, M. J., Simner, P. J., Slover, C. M., Yamano, Y., Nagata, T. D., & Portsmouth, S. (2023). Cefiderocol Treatment for Patients with Multidrug- and Carbapenem-Resistant Pseudomonas aeruginosa Infections in the Compassionate Use Program. Antimicrobial Agents and Chemotherapy, 67(7). https://doi.org/10.1128/aac.00194-23
Vancouver
Satlin MJ, Simner PJ, Slover CM, Yamano Y, Nagata TD, Portsmouth S. Cefiderocol Treatment for Patients with Multidrug- and Carbapenem-Resistant Pseudomonas aeruginosa Infections in the Compassionate Use Program. Antimicrobial Agents and Chemotherapy. 2023;67(7). doi:10.1128/aac.00194-23
BibTeX
@article{Satlin2023,
author = {Satlin, Michael J and Simner, Patricia J and Slover, Christine M and Yamano, Yoshinori and Nagata, Tsutae D and Portsmouth, Simon},
title = {Cefiderocol Treatment for Patients with Multidrug- and Carbapenem-Resistant Pseudomonas aeruginosa Infections in the Compassionate Use Program},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2023},
volume = {67},
number = {7},
doi = {10.1128/aac.00194-23}
}
EUVIMED